High symptom burden in female X-linked chronic granulomatous disease carriers. Read more about High symptom burden in female X-linked chronic granulomatous disease carriers.
A proximal enhancer regulates RORA expression during early human Th17 cell differentiation. Read more about A proximal enhancer regulates RORA expression during early human Th17 cell differentiation.
Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia. Read more about Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia.
Expectations and experience: Parent and patient perspectives regarding treatment for Severe Combined Immunodeficiency (SCID). Read more about Expectations and experience: Parent and patient perspectives regarding treatment for Severe Combined Immunodeficiency (SCID).
Successful newborn screening for SCID in the Navajo Nation. Read more about Successful newborn screening for SCID in the Navajo Nation.
B-cell activating factor (BAFF) is elevated in chronic granulomatous disease. Read more about B-cell activating factor (BAFF) is elevated in chronic granulomatous disease.
Deficient T Cell Receptor Excision Circles (TRECs) in autosomal recessive hyper IgE syndrome caused by DOCK8 mutation: implications for pathogenesis and potential detection by newborn screening. Read more about Deficient T Cell Receptor Excision Circles (TRECs) in autosomal recessive hyper IgE syndrome caused by DOCK8 mutation: implications for pathogenesis and potential detection by newborn screening.
Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey. Read more about Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey.
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Read more about Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Read more about Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations.
